JP2010530354A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530354A5
JP2010530354A5 JP2009544267A JP2009544267A JP2010530354A5 JP 2010530354 A5 JP2010530354 A5 JP 2010530354A5 JP 2009544267 A JP2009544267 A JP 2009544267A JP 2009544267 A JP2009544267 A JP 2009544267A JP 2010530354 A5 JP2010530354 A5 JP 2010530354A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
autoimmune
soluble
dosage unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009544267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530354A (ja
JP5481199B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/088960 external-priority patent/WO2008083228A2/en
Publication of JP2010530354A publication Critical patent/JP2010530354A/ja
Publication of JP2010530354A5 publication Critical patent/JP2010530354A5/ja
Application granted granted Critical
Publication of JP5481199B2 publication Critical patent/JP5481199B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009544267A 2006-12-27 2007-12-27 炎症および自己免疫疾患を治療するための組成物および方法 Expired - Fee Related JP5481199B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87731906P 2006-12-27 2006-12-27
US60/877,319 2006-12-27
US94974207P 2007-07-13 2007-07-13
US60/949,742 2007-07-13
PCT/US2007/088960 WO2008083228A2 (en) 2006-12-27 2007-12-27 Compositions and methods for treating inflammation and auto-immune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013103888A Division JP5926701B2 (ja) 2006-12-27 2013-05-16 炎症および自己免疫疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2010530354A JP2010530354A (ja) 2010-09-09
JP2010530354A5 true JP2010530354A5 (https=) 2011-02-24
JP5481199B2 JP5481199B2 (ja) 2014-04-23

Family

ID=39521467

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009544272A Pending JP2011502954A (ja) 2006-12-27 2007-12-27 免疫応答を刺激する組成物および方法
JP2009544267A Expired - Fee Related JP5481199B2 (ja) 2006-12-27 2007-12-27 炎症および自己免疫疾患を治療するための組成物および方法
JP2013103888A Expired - Fee Related JP5926701B2 (ja) 2006-12-27 2013-05-16 炎症および自己免疫疾患を治療するための組成物および方法
JP2015229316A Withdrawn JP2016035474A (ja) 2006-12-27 2015-11-25 炎症および自己免疫疾患を治療するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009544272A Pending JP2011502954A (ja) 2006-12-27 2007-12-27 免疫応答を刺激する組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013103888A Expired - Fee Related JP5926701B2 (ja) 2006-12-27 2013-05-16 炎症および自己免疫疾患を治療するための組成物および方法
JP2015229316A Withdrawn JP2016035474A (ja) 2006-12-27 2015-11-25 炎症および自己免疫疾患を治療するための組成物および方法

Country Status (6)

Country Link
US (4) US20080206235A1 (https=)
EP (3) EP2124998B8 (https=)
JP (4) JP2011502954A (https=)
AU (2) AU2007339773B2 (https=)
CA (2) CA2673659A1 (https=)
WO (2) WO2008083228A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4392385A (en) * 1984-06-22 1986-01-02 Mizusawa Industrial Chemicals, Ltd. Preparation of synthetic fraipontite
US6891030B2 (en) 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
KR101429013B1 (ko) * 2007-07-02 2014-08-11 삼성전자주식회사 도전성 전사 롤러의 제조방법, 이로부터 제조된 전사롤러및 이를 포함하는 화상형성장치
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
US20110200600A1 (en) * 2008-09-10 2011-08-18 Indiana University Research And Technology Corporation Diagnosis and prognosis of immune disorders using stat4 expression
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
CA2894879A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
CA2912801A1 (en) 2013-05-17 2014-11-20 Medimmune, Llc Receptors for b7-h4
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11306144B2 (en) 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
US20190345246A1 (en) * 2018-05-10 2019-11-14 TympoBio, Inc. Compositions and Methods for Treating Autoimmune Inner Ear Disease
MX2023008000A (es) 2021-01-04 2023-07-13 Mersana Therapeutics Inc Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36107A (en) * 1862-08-05 Improvement in
US202587A (en) * 1878-04-16 Improvement in door-hangers
US12758A (en) * 1855-04-24 chane
GB1268212A (en) * 1968-04-19 1972-03-22 Zaidan Hojin Biseibutsu Tripeptide derivatives
JPS6050743B2 (ja) * 1976-06-02 1985-11-09 旭光学工業株式会社 アパタイト焼結体及びその製造方法
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5278056A (en) * 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US4891719A (en) * 1988-10-03 1990-01-02 Datatape Incorporated Fast closure method for a data signal channel
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
DE69230142T2 (de) * 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
EP0592668B1 (en) 1991-07-03 1999-03-10 Kanebo, Ltd. Method and device for the manufacture of a thermoplastic polyurethane elastomer
US5202332A (en) * 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ251628A (en) * 1992-03-30 1996-07-26 American Home Prod Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
DE4301681C1 (de) * 1993-01-22 1994-10-20 Deutsche Aerospace Airbus Rohrverzweigung zwischen einer Luftleitung und einer Luftdusche
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
WO1995012972A1 (en) 1993-11-08 1995-05-18 Cressy, Wayne, Malcolm Head restraining device
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU705688B2 (en) 1995-11-10 1999-05-27 Cytogen Corporation Peptides which enhance transport across tissues and methods of identifying and using the same
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
EP0793995B1 (en) * 1996-03-05 2001-10-04 Hitachi, Ltd. Method of treating gases containing organohalogen compounds
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6982323B1 (en) * 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
CA2328895A1 (en) 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
WO2000012758A1 (en) 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
US6962980B2 (en) * 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001001137A1 (en) * 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
DE19937656A1 (de) * 1999-08-13 2001-02-15 Aventis Behring Gmbh Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen
WO2002002624A2 (en) * 2000-06-30 2002-01-10 Amgen, Inc. B7-like molecules and uses thereof
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
US6891030B2 (en) * 2000-07-27 2005-05-10 Mayo Foundation For Medical Education And Research T-cell immunoregulatory molecule
US7975021B2 (en) * 2000-10-23 2011-07-05 Clearplay, Inc. Method and user interface for downloading audio and video content filters to a media player
US6562576B2 (en) * 2001-01-04 2003-05-13 Myriad Genetics, Inc. Yeast two-hybrid system and use thereof
US7132511B2 (en) * 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
US20050215727A1 (en) * 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
IL150013A (en) * 2002-06-04 2007-06-17 Gil Hecht Rotary cutting tool
EP1539218A4 (en) * 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
AU2003258714A1 (en) * 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
US7449300B2 (en) * 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
US20050163772A1 (en) * 2003-06-16 2005-07-28 University Of Washington B7S1: an immune modulator
US7334413B2 (en) * 2004-05-07 2008-02-26 Rosemount Aerospace Inc. Apparatus, system and method for observing combustion conditions in a gas turbine engine
DE102004060403A1 (de) * 2004-12-14 2006-07-06 Trützschler GmbH & Co KG Vorrichtung in der Spinnereivorbereitung zur Speisung einer Mehrzahl von Füllschächten, insbesondere Mischer, mit Fasermaterial
US7694100B2 (en) * 2004-12-20 2010-04-06 Intel Corporation Managing system memory resident device management queues
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
CA2611861C (en) * 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
US20070039150A1 (en) * 2005-08-08 2007-02-22 Thomas David L Convertible furniture system comprised of modular convertible box frames and methods of forming various furniture configurations therefrom
KR100779170B1 (ko) * 2005-08-16 2007-11-23 학교법인 포항공과대학교 광양자테 홀 발광소자의 버트 커플링 방법
JP4730263B2 (ja) * 2005-09-21 2011-07-20 富士ゼロックス株式会社 画像処理装置の保守システム
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
CN101399708B (zh) * 2007-09-28 2012-04-04 华为技术有限公司 一种建立网络性能模型的方法和设备
JP2011503104A (ja) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CA2772204A1 (en) * 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection

Similar Documents

Publication Publication Date Title
JP2010530354A5 (https=)
Alhaidar et al. Current treatment of myasthenia gravis
Sethi et al. Pediatric acute kidney injury: new advances in the last decade
Behrens et al. MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
Céspedes et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells
Viganò et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal
Van Vollenhoven Treatment of rheumatoid arthritis: state of the art 2009
AU2013206788B2 (en) Method of providing monoclonal auto-antibodies with desired specificity
JP2016527187A5 (https=)
US10131709B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
JP2018503618A5 (https=)
JP2009544761A5 (https=)
EP1933868A2 (en) Anti-cd3 antibody formulations
Benucci et al. Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
Yu et al. Potent anti‐SARS‐CoV‐2 efficacy of COVID‐19 hyperimmune globulin from vaccine‐immunized plasma
Fornari Caprara et al. Rasmussen encephalitis: clinical features, pathophysiology, and management strategies—a comprehensive literature review
Malik et al. Respiratory syncytial virus infection: treatments and clinical management
Bingham III et al. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial
Rezabakhsh et al. Therapeutic impact of tocilizumab in the setting of severe COVID-19; an Updated and comprehensive review on current evidence
Suzuki et al. MO258 Safety, tolerability, pharmacokinetics and pharmacodynamics of VIS649, an APRIL-neutralizing IgG2 monoclonal antibody, in healthy volunteers: Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study
Rietsema Unexpected recovery of moderate cognitive impairment on treatment with oral methylcobalamin
Chen et al. Investigation of neurological complications after COVID-19 vaccination: report of the clinical scenarios and review of the literature
US20200369763A1 (en) Compositions for interferon blockade and methods of using same
Lee et al. An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis
Liberek et al. Lamivudine therapy for children with chronic hepatitis B